Company performance
Add to research
Loading...
Description
Add to research
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPSTX
- PriceN/A
Trading Information
- Market cap$925.92M
- Float70.95%
- Average Daily Volume (1m)2,284,661
- Average Daily Volume (3m)1,730,311
- EPS-$0.63
Company
- Revenue$150.86M
- Rev growth (1yr)667.19%
- Net income$20.24M
- Gross margin98.19%
- EBITDA margin29.33%
- EBITDA$21.04M
- EV$129.75M
- EV/Revenue0.86
- P/EN/A
- P/S6.12
- P/BN/A
- Debt/EquityN/A
Documents
Add to research
SEC Filings